Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Fluorodeoxyglucose

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    62 result(s) found for: Fluorodeoxyglucose. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2017-002773-19 Sponsor Protocol Number: INCB39110-206 Start Date*: 2018-06-25
    Sponsor Name:Incyte Corporation
    Full Title: An Open-Label Phase 1/2 Study of INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Medical condition: Relapsed or refractory diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012821 Diffuse large B-cell lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005820-17 Sponsor Protocol Number: 90111-24111 Start Date*: 2012-06-07
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Neoadjuvant BIBW 2992 followed by surgery in squamous cell carcinoma of the head and neck: an EORTC NOCI-HNCG window study.
    Medical condition: Squamous cell carcinoma of the head and neck (SCCHN)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender:
    Trial protocol: BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003144-23 Sponsor Protocol Number: 2017/81 Start Date*: 2018-09-05
    Sponsor Name:University of Liège
    Full Title: Treating severe brain-injured patients with apomorphine : a behavioural and neuroimaging study
    Medical condition: Disorders of consciousness
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005220-15 Sponsor Protocol Number: IIS-1-025R-NL_Kamphuisen Start Date*: 2013-10-23
    Sponsor Name:University Medical Center Groningen
    Full Title: Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early diabetes
    Medical condition: type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10045252 Type II diabetes mellitus without mention of complication LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017587-16 Sponsor Protocol Number: 006117 Start Date*: 2010-12-02
    Sponsor Name:Barts Health NHS Trust
    Full Title: Treatment monitoring using FDG-PET/CT and FLT-PET/CT in patients with Hodgkin Lymphoma.
    Medical condition: Hodgkin Lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002692-42 Sponsor Protocol Number: 1.1_2011 Start Date*: 2012-06-20
    Sponsor Name:MUW-Medical University of Vienna,Medizinische Universität Wien
    Full Title: Characterization of myeloma bone lesions - before and during anti-cancer therapy - using 18F-FDG-, 18F-fluoride PET/CT and MRI- a pilot study
    Medical condition: The primary aim of this study is the characterization of WB MRI detected untreated MM bone lesions in consideration of the mineralization status and tumor activity using 18F-fluorid-PET/CT and 18F ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000735-27 Sponsor Protocol Number: FIL_SGN01 Start Date*: 2013-07-23
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: A phase II study of SGN-35 (brentuximab vedotin) of patients with relapsed or refractory Primary mediastinal large B-cell lymphoma (PMLBCL).
    Medical condition: Relapsed or refractory Primary mediastinal large B-cell lymphoma (PMLBCL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2023-000127-36 Sponsor Protocol Number: KIH22001 Start Date*: 2023-04-04
    Sponsor Name:Karolinska Institutet
    Full Title: Evaluating rapamycin treatment in Alzheimer’s disease using positron emission tomography (ERAP)
    Medical condition: Alzheimer's disease (AD) and mild cognitive impairment (MCI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001897 Alzheimer's disease (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000558-71 Sponsor Protocol Number: 9090-11 Start Date*: 2012-07-25
    Sponsor Name:Synta Pharmaceuticals Corp.
    Full Title: An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women with Breast Cancer
    Medical condition: HER2 positive, triple negative breast cancer (TNBC) and hormone-receptor (ER/PR)-positive breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    16.1 10022891 - Investigations 10054057 Progesterone receptor assay positive PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-006035-12 Sponsor Protocol Number: SG035-0004 Start Date*: 2009-03-24
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: A Phase 2 study of SGN-35 in treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL)
    Medical condition: Systemic anaplastic large cell lymphoma (ALCL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10065864 Anaplastic large-cell lymphoma, primary systemic type LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) IT (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-000381-11 Sponsor Protocol Number: CCMK389X2201 Start Date*: 2020-06-16
    Sponsor Name:Novartis Pharma AG
    Full Title: A subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sar...
    Medical condition: Chronic pulmonary sarcoidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037430 Pulmonary sarcoidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) CZ (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002106-13 Sponsor Protocol Number: ATH3G10-005 Start Date*: 2017-09-06
    Sponsor Name:Athera Biotechnologies AB
    Full Title: Double-blind, randomised, placebo-controlled, multicentre, Phase IIa study to investigate the effect of phosphorylcholine human monoclonal antibody (PC-mAb) 3G10 on arterial inflammation, together ...
    Medical condition: Arterial inflammation in subjects with elevated lipoprotein a (Lp[a])
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000022953 10051615 Atherosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002047-24 Sponsor Protocol Number: SAKK56/07 Start Date*: 2008-04-29
    Sponsor Name:Swiss Group for Clinical Cancer Reaserch (SAKK)
    Full Title: Trial SAKK 56/07 Dasatinib first-line treatment in gastrointestinal stromal tumors. A multicenter phase II trial.
    Medical condition: GIST (Gastrointestinal stromal tumor) is a rare disease affecting 15 patients per 1 million individuals and comprising 5% of all sarcomas. Mutations in the genes of KIT or PDGFRA lead to constituti...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051066 Gastrointestinal stromal tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003355-38 Sponsor Protocol Number: D0816C00025 Start Date*: 2019-12-05
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours
    Medical condition: Solid Tumours
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Ongoing) ES (Ongoing) DK (Ongoing) HU (Ongoing) IT (Ongoing) AT (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003237-41 Sponsor Protocol Number: MK-7339-012 Start Date*: 2020-06-23
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by ...
    Medical condition: unresectable, locally advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) HU (Ongoing) LV (Ongoing) DE (Ongoing) PL (Trial now transitioned) EE (Ongoing) FR (Ongoing) GB (GB - no longer in EU/EEA) RO (Ongoing) IT (Ongoing) LT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000939-42 Sponsor Protocol Number: IP-N02 Start Date*: 2012-07-20
    Sponsor Name:Elro Pharma
    Full Title: A non-randomized, open-label, multi-centric dose-finding adaptive phase I/IIa study to assess safety, tolerability, pharmacokinetics and preliminary efficacy of repeated intravenous IPP-204106N adm...
    Medical condition: Solid tumors
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004109-24 Sponsor Protocol Number: FIL_BVHD01 Start Date*: 2014-07-14
    Sponsor Name:Fondazione Italiana Linfomi Onlus
    Full Title: A phase II study of Brentuximab Vedotin (BV) in the treatment of elderly Hodgkin lymphoma (HL) patients at first relapse or with primary refractory disease
    Medical condition: elderly Hodgkin lymphoma (HL) patients at first relapse or with primary refractory disease
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001290-78 Sponsor Protocol Number: 007697 Start Date*: 2012-01-17
    Sponsor Name:Barts Health NHS Trust
    Full Title: Diagnostic accuracy of MRI, diffusion-weighted MRI, FDG-PET/CT and Fluoro-ethyl-choline PET/CT in the detection of lymph node metastases in surgically staged endometrial and cervical carcinoma
    Medical condition: Endometrial and Cervical Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001364-19 Sponsor Protocol Number: BO29563 Start Date*: 2015-12-15
    Sponsor Name:F. HOFFMANN - LA ROCHE LTD.
    Full Title: A phase Ib/II study evaluating the safety and efficacy of MPDL3280A in combination with either obinutuzumab plus bendamustine or obinutuzumab plus CHOP in patients with follicular lymphoma or diffu...
    Medical condition: Follicular lymphoma or diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    20.0 100000004864 10016904 Follicle centre lymphoma, follicular grade I, II, III NOS LLT
    20.0 100000004864 10012820 Diffuse large B-cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002751-42 Sponsor Protocol Number: SGN35-014 Start Date*: 2013-02-18
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas
    Medical condition: CD30-positive mature T-cell lymphomas
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025321 Lymphomas non-Hodgkin's T-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) DE (Completed) ES (Completed) DK (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:35:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA